Angela Estell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angela Estell has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ariana D. Majer
University of Pennsylvania 1 Division of Gastroenterology and Hepatology, Perelman School of Medicine Philadelphia, Pennsylvania
82 shared publications - Christopher A. Natale
Linnaeus Therapeutics, Haddonfield, New Jersey
82 shared publications - Inyoung Lee
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
82 shared publications - J. Kevin Foskett
University of Pennsylvania
82 shared publications - Jillian Weissenrieder
Department of Physiology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
82 shared publications - Martin Carroll
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
82 shared publications
Latest Publications
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S3. GPER expression grossly does not correlate with AML outcome and mutation status (A) GPER expression stratified by ELN2017. (B) GPER expression stratified by FLT3-ITD mutation status. (C) GPER expression stratified by different AML fusion proteins. All data were acquired from the BEAT-AML dataset. P-values were calculated via one-way ANOVA multiple comparisons (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S3. GPER expression grossly does not correlate with AML outcome and mutation status (A) GPER expression stratified by ELN2017. (B) GPER expression stratified by FLT3-ITD mutation status. (C) GPER expression stratified by different AML fusion proteins. All data were acquired from the BEAT-AML dataset. P-values were calculated via one-way ANOVA multiple comparisons (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
(A and C) Representative DCF histograms of (A) U937 and (C) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801 at indicated time points. (B and D) Summary graph of median fluorescence intensity (MFI) of (B) U937 and (D) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801. 3 replicates were analyzed per condition. Statistical analysis was done via one-way ANOVA with multiple comparisons was used for panels B and D (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
(A and C) Representative DCF histograms of (A) U937 and (C) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801 at indicated time points. (B and D) Summary graph of median fluorescence intensity (MFI) of (B) U937 and (D) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801. 3 replicates were analyzed per condition. Statistical analysis was done via one-way ANOVA with multiple comparisons was used for panels B and D (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Data from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 inhibits AML colony formation. A, Colony formation assay of primary AML cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. B, Colony formation of normal mononuclear cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. CFU: Colony forming units. BFU: Blast forming units. CFU-G: CFU-granulocytes. CFU-M: CFU-monocytes. CFU-GM: CFU-granulocyte/monocyte. BFU-E: BFU-Erythrocytes. CFU-GEMM: CFU-granulocyte/erythrocyte/monocyte/megakaryocyte. CFU-E: CFU-erythrocyte P values were calculated using t tests (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 inhibits AML colony formation. A, Colony formation assay of primary AML cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. B, Colony formation of normal mononuclear cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. CFU: Colony forming units. BFU: Blast forming units. CFU-G: CFU-granulocytes. CFU-M: CFU-monocytes. CFU-GM: CFU-granulocyte/monocyte. BFU-E: BFU-Erythrocytes. CFU-GEMM: CFU-granulocyte/erythrocyte/monocyte/megakaryocyte. CFU-E: CFU-erythrocyte P values were calculated using t tests (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S13. IRE1⍺ inhibitor blocks LNS8801-induced caspase cleavage Western blot of U937 cells treated with 250nM LNS8801 and/or 1uM IRE1⍺ inhibitor Kira6 or 5uM PERK inhibitor GSK414 for 24 hours. Western blot quantification was done by normalizing each band to the respective actin band.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S13. IRE1⍺ inhibitor blocks LNS8801-induced caspase cleavage Western blot of U937 cells treated with 250nM LNS8801 and/or 1uM IRE1⍺ inhibitor Kira6 or 5uM PERK inhibitor GSK414 for 24 hours. Western blot quantification was done by normalizing each band to the respective actin band.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Data from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.